Retraction Note to: Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate (Aging Clinical and Experimental Research, (2005), 17, 2, (157-163), 10.1007/BF03324589);Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate

Aging Clinical and Experimental Research

Volumn 17, Issue 2, 2005, Pages 157-163

  Iwamoto, Jun ^a   Takeda, Tsuyoshi ^a   Sato, Yoshihiro ^b   Uzawa, Mitsuyoshi ^c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mitate Hospital   (Japan)

^c Keiyu Orthopedic Hospital   (Japan)

Author keywords

Alendronate; Bone mineral density (BMD); Elderly women; Osteoporosis; Whole body vibration exercise

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CALCIUM; COLLAGEN TYPE 1; PHOSPHORUS;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ARTICLE; BACKACHE; BODY MASS; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FEMALE; HUMAN; MACHINE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE; WHOLE BODY VIBRATION; BLOOD; BONE REMODELING; CHRONIC DISEASE; DRUG EFFECT; FALLING; LUMBAR VERTEBRA; MIDDLE AGED; STATISTICS; VIBRATION;

ACCIDENTAL FALLS; AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; BACK PAIN; BONE DENSITY; BONE REMODELING; CALCIUM; CHRONIC DISEASE; EXERCISE; FEMALE; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PHOSPHORUS; VIBRATION;

EID: 23244451615     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: 10.1007/s40520-019-01373-6     Document Type: Erratum

References (31)

1. Masud T, Giannini S. Preventing osteoporotic fractures with bisphosphonates: a review of the efficacy and tolerability. Aging Clin Exp Res 2003; 15: 89-98.
2. Shiraki M, Kushida K, Fukunaga M, et al. A double-masked multicenter comparative study between alendronate and alfa-calcidol in Japanese patients with osteoporosis. Osteoporos Int 1999; 10: 183-92.
3. Kushida K, Shiraki M, Nakamura T, et al. The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res 2002; 63: 606-20.
4. Miyakoshi N, Itoi E, Kobayashi M, Kodama H. Impact of postural deformities and spinal mobility on quality of life in postmenopausal osteoporosis. Osteoporos Int 2003; 14: 1007-12.
5. Iwamoto J, Takeda T, Ichimura S, Uzawa M. Comparative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly women with symptomatic vertebral fractures. Keio J Med 2003; 52: 230-5.
6. Pappagallo M, Breuer B, Schneider A, Sperber K. Treatment of chronic mechanical spinal pain with intravenous pamidronate: a review of medical records. J Pain Symptom Manage 2003; 26: 678-83.
7. Nevitt MC, Thompson DE, Black DM, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch Intern Med 2000; 160: 77-85.
8. Bosco C, Cardinale M, Tsarpela O. Influence of vibration on mechanical power and electromyogram activity in human arm flexor muscles. Eur J Appl Physiol Occup Physiol 1999; 79: 306-11.
9. Russo CR, Lauretani F, Bandinelli S, et al. High-frequency vibration training increases muscle power in postmenopausal women. Arch Phys Med Rehabil 2003; 84: 1854-7.
10. Kerchan-Schindl K, Grampp S, Henk C, et al. Whole-body vibration exercise leads to alterations in muscle blood volume. Clin Physiol 2001; 3: 377-82.
11. Torvinen S, Kannus P, Siebanen H. Effect of a vibration exposure on muscular performance and body balance. Randomized crossover study. Clin Physiol Funct Imaging 2002; 22: 145-52.
12. Rittweger J, Just K, Kautzsch K, Reeg P, Felsenberg D. Treatment of chronic lower back pain with lumbar extension and whole-body vibration exercise: a randomized controlled trial. Spine 2002; 27: 1829-34.
13. Orimo H, Sugioka Y, Fukunaga M, et al. Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 1998; 16: 139-50.
14. Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001; 19: 331-7.
15. Lorish CD, Maisiak R. The face scale: a brief, nonverbal method for assessing patient mood. Arthritis Rheum 1986; 29: 906-9.
16. Agarwala S, Sule A, Pai BU, Joshi VR. Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford) 2002; 41: 346-7.
17. Gangji V, Appelboom T. Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol 1999; 18: 266-7.
18. Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 1994; 74: 2949-55.
19. Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001; 14: 529-33.
20. Hortobagyi GN, Terhiault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785-91.
21. Siris E, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res 1998; 13: 1032-8.
22. Nishikaku F, Nakayama T, Nakatsuka M. Analgesic property of bisphosphonate, etidronate in animal models. Jpn Pharmacol Ther 1998; 26: 457-63 (in Japanese).
23. Tanaka T, Nakayama T, Katsumata T. Etidronate: therapeutic agent for osteoporosis possessing analgesic effect. Bio Clinica 2001; 16: 57-61 (in Japanese).
24. Iwamoto J, Takeda T, Ichimura S. Transient relief of metastatic cancer bone pain by oral administration of etidronate. J Bone Miner Metab 2002; 20: 228-34.
25. Cantatore FP, Acquista CA, Pipitone V. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 1999; 26: 2318-23.
26. Torvinen S, Kannus P, Sievanen H, et al. Effect of 8-month vertical body vibration on bone, muscle performance, and bone balance: a randomized controlled study. J Bone Miner Res 2003; 18: 876-84.
27. Rubin C, Xu G, Judex S. The anabolic activity of bone tissue, suppressed by disuse, is normalized by brief exposure to extremely low-magnitude mechanical stimuli. FASEB J 2003; 15: 2225-9.
28. Rubin C, Turner S, Brain S, Mallinckrodt C, McLeod K. Low mechanical signals strengthen long bones. Nature 2001; 412: 603-4.
29. Rubin C, Turner S, Muller R, et al. Quantity and quality of trabecular bone in the femur are enhanced by a strongly anabolic, noninvasive mechanical intervention. J Bone Miner Res 2002; 17: 349-57.
30. Rubin C, Turner S, Mallinckrodt C, Jerome C, McLeod K, Bain S. Mechanical strain, induced noninvasively in the high-frequency domain, is anabolic to cancellous bone, but not cortical bone. Bone 2002; 30: 445-52.
31. Cardinale M, Pope MH. The effects of whole body vibration on humans: dangerous or advantageous? Acta Physiol Hung 2003; 90: 195-206.